Accounting for clinical action reduces estimates of gender disparities in lipid management for diabetic veterans

Journal of General Internal Medicine

Volumn 28, Issue SUPPL.2, 2013, Pages

  Vimalananda, Varsha G ^a,b   Miller, Donald R ^a,c   Hofer, Timothy P ^a,d,e   Holleman, Robert G ^a   Klamerus, Mandi L ^a   Kerr, Eve A ^a,d,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Diabetes; Disparities; Quality of care; Statins; Women

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETIC PATIENT; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SEX DIFFERENCE; VETERAN;

AGED; CHOLESTEROL, LDL; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; DISEASE MANAGEMENT; FEMALE; HEALTHCARE DISPARITIES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES; VETERANS; VETERANS HEALTH;

EID: 84892932502     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2340-5     Document Type: Article

References (54)

1. Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M, et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care. 2008;31(1):69-74.
2. Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008;31(7):1389-91.
3. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: A meta-analysis. Arch Intern Med. 2002;162(15):1737-45.
4. Shalev V, Chodick G, Heymann AD, Kokia E. Gender differences in healthcare utilization and medical indicators among patients with diabetes. Public Health. 2005;119(1):45-9.
5. Tseng CL, Sambamoorthi U, Rajan M, Tiwari A, Frayne S, Findley P, et al. Are there gender differences in diabetes care among elderly Medicare enrolled veterans J Gen Intern Med. 2006;21(Suppl 3):S47-53.
6. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005;28(3):514-20.
7. Winston GJ, Barr RG, Carrasquillo O, Bertoni AG, Shea S. Sex and racial/ethnic differences in cardiovascular disease risk factor treatment and control among individuals with diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2009;32(8):1467-9.
8. Vimalananda VG, Miller DR, Palnati M, Christiansen CL, Fincke BG. Gender disparities in lipid-lowering therapy among veterans with diabetes. Womens Health Issues. 2011;21(4 Suppl):S176-81.
9. Wright SM, Schaefer J, Reyes-Harvey E, Francis J. Comparing the care of women and men veterans in the VA. Washington, D.C.: VA Office of Analytics and Business Intelligence White Paper to the U.S. Assistant Deputy Under Secretary for Quality and Patient Safety, Veterans Health Administration; 2012.
10. Asch SM, McGlynn EA, Hogan MM, Hayward RA, Shekelle P, Rubenstein L, et al. Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med. 2004;141(12):938-45.
11. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, et al. Diabetes care quality in the Veterans Affairs health care system and commercial managed care: The TRIAD study. Ann Intern Med. 2004;141 (4):272-81.
12. Jha AK, Perlin JB, Steinman MA, Peabody JW, Ayanian JZ. Quality of ambulatory care for women and men in the Veterans Affairs health care system. J Gen Intern Med. 2005;20(8):762-5.
13. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: An open letter to the adult treatment panel IV of the national institutes of health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2-5.
14. Kerr EA, Smith DM, Hogan MM, Hofer TP, Krein SL, Bermann M, et al. Building a better quality measure: Are some patients with 'poor quality' actually getting good care Med Care. 2003;41(10):1173-82.
15. Hayward RA, Hofer TP, Vijan S. Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem. Ann Intern Med. 2006;145:520-30.
16. Drozda J Jr, Messer JV, Spertus J, Abramowitz B, Alexander K, Beam CT, et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: A report of the American College of Cardiology Foundation/American Heart Association task force on performance measures and the American Medical Association- Physician Consortium for Performance Improvement. Circulation. 2011;124(2):248-70.
17. Assessing quality of care for diabetes - conference final report. [Internet].: AHRQ; 2008; cited December 10, 2012]. Available from: Http://www.ahrq.gov/qual/diabetescare/.
18. Selby JV, Uratsu CS, Fireman B, Schmittdiel JA, Peng T, Rodondi N, et al. Treatment intensification and risk factor control: Toward more clinically relevant quality measures. Med Care. 2009;47(4):395-402.
19. Kerr EA, Lucatorto MA, Holleman R, Hogan MM, Klamerus ML, Hofer TP, et al. Monitoring performance for blood pressure management among patients with diabetes mellitus: Too much of a good thing Arch Intern Med. 2012;28:1-8.
20. Yu W, Ravelo A, Wagner TH, Phibbs CS, Bhandari A, Chen S, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev. 2003;60(3 Suppl):146S-67.
21. Kerr EA, Zikmund-Fisher BJ, Klamerus ML, Subramanian U, Hogan MM, Hofer TP. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med. 2008;148(10):717-27.
22. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29(3):725-31.
23. Beard AJ, Hofer TP, Lucatorto M, Downs JR, Klamerus ML, Holleman R, et al. Assessing appropriateness of lipid management among patients with diabetes: Moving from target to treatment. (in press, Circulation: Cardiovascular Quality and Outcomes).
24. O'Connor PJ, Bodkin NL, Fradkin J, Glasgow RE, Greenfield S, Gregg E, et al. Diabetes performance measures: Current status and future directions. Diabetes Care. 2011;34(7):1651-9.
25. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371(9607):117-25.
26. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361 (9374):2005-16.
27. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360 (9326):7-22.
28. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96.
29. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet. 2010;376(9753):1658-69.
30. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA. 2005;294(19): 2437-45.
31. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37(9):846-57.
32. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-16.
33. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. description and validation. Med Care. 1988;26(8):814-23.
34. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005;28(3):514-20.
35. Kim C, Kerr EA, Bernstein SJ, Krein SL. Gender disparities in lipid management: The presence of disparities depends on the quality measure. Am J Manage Care. 2006;12(3):133-6.
36. Pregler J, Freund KM, Kleinman M, Phipps MG, Fife RS, Gams B, et al. The heart truth professional education campaign on women and heart disease: Needs assessment and evaluation results. J Women's Health (Larchmt). 2009;18(10):1541-7.
37. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: A major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973-85.
38. Nau DP, Ellis JJ, Kline-Rogers EM, Mallya U, Eagle KA, Erickson SR. Gender and perceived severity of cardiac disease: Evidence that women are "tougher". Am J Med. 2005;118(11):1256-61.
39. Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3(2):120-7.
40. Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' Perspectives on nonadherence to statin therapy: A focus-group study. Perm J. 2010;14(1):4-10.
41. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195(1):7-16.
42. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: A systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-21.
43. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Metaanalysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572-82.
44. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360 (9346):1623-30.
45. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):640-51.
46. Mosca L, Jones W, King K, Ouyang P, Redberg R, Hill M. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women's Heart Disease and Stroke Campaign Task Force. Arch Fam Med. 2000;9:506-15.
47. Cooper G, Goodwin M, Stange K. The delivery of preventive services for patient symptoms. Am J Prev Med. 2001;21:177-81.
48. Stange K, Flocke S, Goodwin M, Kelly R, Zyzanski S. Direct observation of rates of preventive service delivery in community family practice. Prev Med. 2000;31:167-76.
49. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
50. Rosenberg H, Allard D. Women and statin use: A women's health advocacy perspective. Scand Cardiovasc J. 2008;42(4):268-73.
51. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A metaanalysis. JAMA. 2011;24:2556-64.
52. VA Pharmacy Benefits Management. Statin Criteria for Use (Pravastatin, Rosuvastatin, Atorvastatin, Fluvastatin, Fluvastatin XL); VHA Pharmacy Benefits Management (PBM) Services, Medical Advisory Panel (MAP) and VISN Pharmacist Executives (VPEs); 2011. Accessed May 8, 2012, at http://www.pbm.va.gov.
53. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEJM. 2004;350(15):1495-504.
54. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-45.